# Francois Valencony > Francois Valencony is a Series C investor at General Inception backing Health Care. See 16 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [General Inception](https://shizune.co/investors/profile/general-inception) - Location: Boston, United States - Total investments: 16 - Last investment: Apr 2019 - Lead investor: 31% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/francois-valencony-06b84b2 Francois Valencony is a Series C investor at General Inception in Boston focused on Health Care and Life Science. Francois Valencony - Managing Partner & Executive Officer @ Mérieux Equity Partners ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 3 | 19% | | Life Science | 2 | 13% | | Therapeutics | 2 | 13% | | Biotechnology | 2 | 13% | | Software | 1 | 6% | 6 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series C | 2 | 13% | | Series B | 1 | 6% | | Series D | 1 | 6% | | Funding Round | 1 | 6% | | Private Equity | 1 | 6% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 2 | 13% | | Luxembourg | 1 | 6% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M | Series C | Apr 04, 2019 | | | Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M | Series C | Apr 04, 2019 | | | Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M | Series C | Dec 19, 2018 | | | Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M | Series C | Dec 19, 2018 | | | Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $55.5M | Series C | Feb 28, 2018 | | | Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $55.5M | Series C | Feb 28, 2018 | | | Proclara Biosciences | NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $17M | Series D | Mar 25, 2014 | | | Lavorel Medicare | Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | | | Jun 20, 2013 | | | Lavorel Medicare | Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | | | Jun 20, 2013 | | | Lavorel Medicare | Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | | Private Equity | May 27, 2013 | | 10 of 16 investments shown. ## Co-investors - [Mérieux Equity Partners](https://shizune.co/investors/profile/m%C3%A9rieux-equity-partners) — VC Fund, 9 deals together - [Mérieux Equity Partners](https://shizune.co/investors/profile/merieux-equity-partners) — VC Fund, 7 deals together - [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 6 deals together - [NanoDimension](https://shizune.co/investors/profile/nanodimension) — VC Fund, 6 deals together - [+ND Capital](https://shizune.co/investors/profile/nd-capital) — VC Fund, 6 deals together - [Paladin Capital Group](https://shizune.co/investors/profile/paladin-capital-group) — VC Fund, 6 deals together ## About General Inception VC Fund · San Francisco, United States General Inception is an institutional co-founder for science-based companies bringing specialized expertise, operational resources and capital to innovation. 5 contacts available at General Inception. | Name | Title | Profile | | --- | --- | --- | | Francois Valencony | Chief Investment & Business Officer | https://shizune.co/investors/profile/francois-valencony | | Jeff Rieger | Fractional Executive | https://shizune.co/investors/profile/jeff-rieger | | Paul Conley | CEO & Co-founder | https://shizune.co/investors/profile/dr-paul-conley | | Soumya Ray | Fraction Executive, Advisor and Company Builder | https://shizune.co/investors/profile/soumya-ray-6e41 | | Venkat Reddy | CSO | https://shizune.co/investors/profile/venkat-reddy-ebe8 | ## Similar investors ### Similar stage - [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund - [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund - [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund ## FAQ ### What does Francois Valencony invest in? Francois Valencony invests primarily in Health Care, Life Science and Therapeutics startups, most often at Series C and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Francois Valencony last invest? The most recent investment recorded for Francois Valencony closed in Apr 2019. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co